On July 6, 2020 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that, based on currently available information, it estimates that both reported and organic revenue1 growth will be approximately 10% for the second quarter ended June 27, 2020 (Press release, Thermo Fisher Scientific, JUL 6, 2020, View Source [SID1234561707]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The better-than-expected organic revenue growth was primarily driven by strong global sales of PCR-based tests and other products and services supporting the COVID-19 response, which contributed more than $1.4 billion of revenue in the second quarter and reflects the scale of the company’s role in helping customers battle the pandemic.

Thermo Fisher will release its financial results for the second quarter on Wednesday, July 22, 2020, before the market opens, and will hold a conference call to discuss those results and provide a business update on the same day at 8:30 a.m. ET.

To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S. The conference ID is 1239877. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under "Financial Results." A replay of the call will be available under "Webcasts and Presentations" through Friday, July 31, 2020.

On July 6, 2020 Centene Corporation (NYSE: CNC) reported that it will release its 2020 second quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, July 28, 2020, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results. Michael F. Neidorff, Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke, Executive Vice President and Chief Financial Officer, of Centene Corporation will host the call (Press release, Centene , JUL 6, 2020, View Source [SID1234561706]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 0580014, to expedite caller registration; or via a live, audio webcast on the Company’s website at www.centene.com, under the Investors section.

A webcast replay will be available for on-demand listening shortly after the completion of the call for the next 12 months or until 11:59 p.m. (Eastern Time) on Tuesday, July 27, 2021, at the aforementioned URL. In addition, a digital audio playback will be available until 9 a.m. (Eastern Time) on Tuesday, August 4, 2020, by dialing 1-877-344-7529 in the U.S. and Canada, or +1-412-317-0088 from abroad, and entering access code 10145373.

On July 6, 2020 Haemonetics Corporation (NYSE:HAE) reported that the Company intends to publish first quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesday, August 4, 2020 (Press release, Haemonetics, JUL 6, 2020, View Source [SID1234561705]). The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on August 4, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call can be accessed with the following information:

A live webcast of the call can be accessed on Haemonetics’ investor relations website. Webcast Link: View Source

A webcast replay will be available August 4, 2020 after 11:00 am EDT.

On July 6, 2020 McKesson Corporation (NYSE:MCK) reported that it will release its first quarter fiscal 2021 financial results before market open on Monday, August 3, 2020 (Press release, McKesson, JUL 6, 2020, View Source [SID1234561704]). The company will host a live webcast of the earnings conference call for investors at 8:00 AM Eastern Time to review its financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast will be available on McKesson’s Investor Relations website at View Source, along with the company’s earnings press release, financial tables and slide presentation.

On July 6, 2020 Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, reported preliminary unaudited net revenue of $75.5 million for the second quarter of 2020, compared to $102.6 million for the second quarter of 2019 (Press release, Pacira Pharmaceuticals, JUL 6, 2020, View Source [SID1234561703]). During the second quarter of 2020, average daily sales of EXPAREL (bupivacaine liposome injectable suspension) were 30 percent, 81 percent and 107 percent of the prior year for the months of April, May, and June, respectively. During the second quarter of 2020, the Company’s product sales were negatively impacted by the COVID-19 pandemic, which mandated significant postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions began to lift on a state-by-state basis in April 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very encouraged by the rapid recovery and consistent uptake in EXPAREL sales and ordering accounts on a weekly basis since the peak of the COVID-19 pandemic impact in April," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "Ambulatory surgical centers have quickly returned to the operating room to accommodate patients who were required to wait for important surgical interventions during COVID-19-related shutdowns. These customers have been key to our return to year-over-year growth and underscore our investment in working closely with our anesthesia partners to broaden the use of long-acting EXPAREL regional approaches as a cornerstone for multimodal opioid-sparing strategies that continue to enable the shift of inpatient procedures to the 23-hour stay environment."

Second Quarter Financial Highlights

•Net product sales of EXPAREL/bupivacaine liposome injectable suspension for the second quarter of 2020 were $73.8 million, compared to $99.8 million in the same period in 2019.
•EXPAREL net product sales for the second quarter of 2020 were $73.0 million, compared to $98.9 million in the same period in 2019. Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice for the second quarter of 2020 were $0.8 million, compared to $0.9 million in the same period in 2019.
•iovera° net product sales for the second quarter of 2020 were $1.4 million, compared to $2.0 million in the same period in 2019. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company.
•Royalty revenue for the second quarter of 2020 was $0.3 million, compared to $0.8 million for the same period in 2019.

The financial information included in this press release is preliminary, unaudited and subject to adjustment. It does not present all information necessary for an understanding of the company’s second quarter financial results for 2020. Pacira expects to report its complete financial results for the second quarter and first half of 2020 during the Company’s conference call scheduled for August 2020.